Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


C=X bonded directly to the five-membered hetero ring by nonionic bonding (X is chalcogen)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514359000 - Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)

514408000 - The five-membered hetero ring consists of one nitrogen and four carbons

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20120184593LAMININ-332 PRODUCTION STIMULATING COMPOSITION - Disclosed is a novel composition which has a function of stimulating production of laminin-332. The composition is stable and safe, and can be used routinely. Specifically disclosed is a laminin-332 production stimulating composition which contains one or more compounds selected from the group consisting of D-alanine, D-hydroxyproline, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving a skin condition. The skin condition may include, but is not limited to a photoaging, wrinkles, a rough skin, fine wrinkles and a dry skin. The composition may be used for an external preparation for the skin or a food.07-19-2012
20080280970DEUTERIUM-ENRICHED ATORVASTATIN - The present application describes deuterium-enriched atorvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.11-13-2008
20130079381ETOMIDATE ANALOGUES THAT DO NOT INHIBIT ADRENOCORTICAL STEROID SYNTHESIS - The invention is directed to compounds according to formula (I): where R03-28-2013
20100160408VILDAGLIPTIN FOR TREATING GENERAL PERIPHERAL NEUROPATHIES - The present invention is directed to use of a Dipeptidyl peptidase IV inhibitor for treating general peripheral neuropathies, in particular, the present invention provides a method for the prevention, delay of progression, or the treatment of general peripheral neuropathies in a patient in need thereof, by administering an effective amount of vildagliptin or a pharmaceutically acceptable salt thereof.06-24-2010
20100144828CAFFEOYLQUINIC ACID DERIVATIVES CONTAINING NITROGEN, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USAGE THEREOF - The present invention provides caffeoylquinic acid derivatives and a method of preparing for the same, and also provides pharmaceutical compositions containing caffeoylquinic acid derivatives, and uses of caffeoylquinic acid derivatives in preparation of a medicament for the treatment or prophylaxis of virus diseases, in particular, uses of respiratory syncytial virus and hepatitis B virus, which has the characteristics of safety, high effectiveness and low toxicity.06-10-2010
20100041731SOLID STATES OF ATORVASTATIN POTASSIUM - Atorvastatin potassium crystalline Forms A, B, E, F, and G are provided. Also provided are methods of preparing atorvastatin potassium crystalline Forms A, B, E, F, and G. Atorvastatin potassium crystalline Forms A, B, E, F, and G may be used to prepare pharmaceutical compositions useful for the treatment of hypercholesterolemia or hyperlipidemia.02-18-2010
201001057545-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY - The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof,04-29-2010
20100093826ATROPISOMER OF PYRROLE DERIVATIVE - [Object] A prophylactic or therapeutic agent for a cardiovascular disease is provided.04-15-2010
20090093535Method and composition for treating heart failure - A method and composition for treating, preventing or ameliorating heart failure, cardiac hypertrophy, and/or myocardial dysfunction includes administering a therapeutically effective amount of a HDAC inhibitor, such as phenylbutyrate, in combination with an ACE inhibitor, such as captopril.04-09-2009
20090093534Mu opioid receptor ligands: methods of use and synthesis - Novel compounds and compositions including those compounds, as well as methods of using and making the compounds are herein described. The compounds are useful in therapeutic applications, including modulation of disease or disease symptoms in a subject (e.g., mammal, human, dog, cat, horse). The compounds are useful as modulators of the mu opioid receptor (MOR) through their binding affinity with that receptor.04-09-2009
20130065935Novel Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 - The invention features compounds and methods relating to novel hydroxy-proline analog inhibitors of the ASCT1 and ASCT2 neutral amino acid transporters. These analogs are potent and selective inhibitors of ASCT2 and ASCT1-mediated amino acid transport as evidenced by significantly reduced glutamine or alanine transport-associated currents or radiolabeled substrate (amino acid) uptake in 03-14-2013
20090012150Stablized Pharmaceutical Composition Comprising an Amorphous Active Substance - The invention relates to the pharmaceutical composition comprising the amorphous active substance which is atorvastatin calcium. The process of stabilization of the pharmaceutical composition comprising the pharmaceutical formulation with amorphous atorvastatin calcium, the process of stabilization of the pharmaceutical formulation comprising amorphous atorvastatin calcium and the process of stabilization of atorvastatin calcium in an amorphous form is described.01-08-2009
20090062371ORAL PREPARATION FOR PROMOTING SYNTHESIS OF TISSUE COLLAGEN - An object of the present invention is to provide an oral preparation for promoting synthesis of tissue collagen, an oral preparation for promoting healing of skin wounds or an oral preparation for preventing or improving skin wrinkles or sagging, which is safe and has an excellent effect. The present invention can provide an oral preparation for promoting synthesis of tissue collagen, an oral preparation for promoting healing of skin wounds or an oral preparation for preventing or improving skin wrinkles or sagging, which comprises hydroxyproline or a salt thereof as an active ingredient.03-05-2009
20100056602Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors - The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.03-04-2010
20090076125DEUTERIUM-ENRICHED GLIMEPIRIDE - The present application describes deuterium-enriched glimepiride, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20110281928Process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof - The present invention relates to a process for the preparation of zofenopril and its pharmaceutically acceptable salts and a pharmaceutical composition thereof. The present invention also provides structurally novel compounds, which are useful intermediates in the synthesis of zofenopril.11-17-2011
20100317711STEM-LIKE CELLS AND METHOD FOR REPROGRAMMING ADULT MAMMALIAN SOMATIC CELLS - A new use is provided for small molecule inhibitors of Oct4 and Sox 2 as a cellular reprogramming agent and a method of reprogramming adult mammalian somatic cells into stem-like cells is provided, using small molecule inhibitors of Oct4 and Sox 2 without the need of any material derived from embryos or fetuses, and without the need of potentially harmful transfecting vectors. Stem-like cells created by the present invention can be induced to differentiate into terminally differentiated adult somatic cells, such as, for example, neuronal cells.12-16-2010
20120289575Topical antimicrobial compositions - Disclosed are topical antimicrobial compositions. The compositions are useful for disinfecting and treating microbial infections of the skin or mucosa of humans and animals. The antimicrobial compositions include a salt of amino acid anion and quaternary ammonium cation, comprising the general formula:11-15-2012
20110288146DIRECTLY COMPRESSIBLE GRANULAR MICROCRYSTALLINE CELLULOSE BASED, EXCIPIENT, MANUFACTURING PROCESS AND USE THEREOF - An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API.11-24-2011
20090018182Crystalline forms of atorvastatin - Novel forms of atorvastatin hemi-calcium have been prepared and characterized. These novel forms are particularly useful in pharmaceutical compositions.01-15-2009
20090298907METHOD FOR THE PREPARATION OF 4-FLUORO-ALPHA-[2-METHYL-1-OXOPROPYL]-y-OXO-N-BETA-DIPHENYLBENZENEBUTANAM- IDE AND PRODUCTS THEREFROM - A method for the preparation of 4-fluoro-α-[2-methyl-1-oxopropyl]-y-oxo-N-β-diphenylbenzenebutanamide also known as 2-[2-(4-fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxo-pentanoic acid phenylamide of the formula I containing about 0.1% or less of α-[2-methyl-1-oxopropyl]-γ-oxo-N-p-diphenylbenzene butanamide, about 0.05% or less of difluoro-α-[2-methyl-1-oxopropyl]-y-oxo-N-β-diphenylbenzene butanamide and about 0.1% or less of 3-[2-(4-Fluorophenyl)-2-oxo-1-phenyl-ethoxy]-4-methyl-pent-2-enoic acid phenylamide.12-03-2009
20110263674C-NITROSO-DERIVED NITROXYL DONORS - Active compounds of Formula I are described:10-27-2011
20100113556NOVEL CRYSTAL FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES - The present invention provides novel crystalline forms D1 and D2 of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt, and hydrates thereof. The crystalline forms D05-06-2010
20110201664Methods and Compositions for Treatment of Prostate Intraepithelial Neoplasia - Provided herein are methods of treatment of prostate intraepithelial neoplasia (PIN) by administering bexarotene. Also provided are pharmaceutical compositions and dosing regimens.08-18-2011
20120065241THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS - Pyrrole derivatives are disclosed as agents for the treatment and prevention of neuropathies and neurodegenerative diseases characterized by the presence of axonal blockages, impaired axonal transport or impaired trafficking of vesicles in neurons.03-15-2012
20100249207SYNTHESIS OF PYRROLIDINE COMPOUNDS - Provided are methods for the preparation of certain substituted pyrrolidine compounds, forms of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride, and methods for preparing and using these forms.09-30-2010
20100249206MODIFIED LYSINE-MIMETIC COMPOUNDS - Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.09-30-2010
20130217748COSMETIC CLEANING AGENT - A cosmetic cleaning agent, comprises: in a cosmetic carrier: (a) greater than or equal to 12 wt % of a surfactant mixture comprising (i) at least one anionic surfactant and (ii) at least one zwitterionic/amphoteric surfactant in a weight ratio (i):(ii) of (2,5-3,5):1; (b) at least one cationic copolymer comprising (meth)acrylamide and dialkyldiallylammonium salts as the monomers; and (c) at least one opacifier and/or one pearlizer; wherein the quantities are based on the total weight of the cleaning agent. A method of producing a stable turbid and/or pearlescent cosmetic cleaning agent comprises: combining (a) at least one anionic surfactant and (b) at least one zwitterionic and/or an amphoteric surfactant to produce a surfactant combination; and combining, at room temperature, the surfactant combination with, (c) at least one cationic copolymer comprising (meth)acrylamide and dialkyldiallylammonium salts as the monomers, and (d) at least one opacifier and/or one pearlizer.08-22-2013
20100120888ATORVASTATIN STRONTIUM SALT AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - This invention provides atorvastatin strontium salt or its hydrates or polymorphs having improved water solubility, which is useful for the prevention or treatment of hyperlipidemia and hypercholesterolemia, and a pharmaceutical composition comprising same.05-13-2010
20100081702PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF HEPATITIS - Object The present invention provides a pharmaceutical composition for prophylaxis or treatment of hepatitis.04-01-2010
20090042970METHODS AND DEVICES FOR DESMOPRESSIN DRUG DELIVERY - Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.02-12-2009
20100099735METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI).04-22-2010
20080275104METHODS OF TREATING JUVENILE TYPE 1 DIABETES MELLITUS - The present disclosure describes methods for treating Type 1 diabetes mellitus in juveniles. This treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such as a statin.11-06-2008
20080207733Composition for the Treatment of Vitiligo - The present invention is related with the field of dermatology and in particular with a solution that may be used in those of cosmetics and medicine, useful for the treatment of lesions caused by vitiligo. The amino acid L-Proline is the active principle of the subject composition of the present invention and it stimulates the synthesis of the skin melanic pigment as well as the reproduction of melanocytes. L-Proline does not cause severe side effects as demonstrated by toxicological and clinical studies performed. The vtechnical objective of the present invention is to achieve a synthetic product, effective in the treatment of vitiligo, with no toxic effects or relapsing.08-28-2008
20080280969Novel Compounds - The invention provides a compound of formula (I), pharmaceutical compositions thereof, and methods of treatment using the same.11-13-2008
20090264497STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-COA REDUCTASE INHIBITOR - Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to 10-22-2009
20080269314Process for Forming Amorphous Atorvastatin - A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.10-30-2008
20090012151Novel Compounds 951 - The present invention relates to amide compounds useful as pharmaceuticals for treating respiratory disorders such as asthma, rhinitis and COPD.01-08-2009
20090005432PHARMACEUTICAL COMPOSITIONS INCLUDING LOW DOSAGES OF DESMOPRESSIN - The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed.01-01-2009
20090054512USE OF ORGANIC COMPOUNDS - A method for improving glucose control by administering a DPP-IV inhibitor to a patient in need thereof, before or with the evening meal.02-26-2009
20110144181Pharmaceutical Compositions of Amorphous Atorvasta and Process for Preparing Same - Solid pharmaceutical compositions containing atorvastatin are disclosed. The compositions include a solid dispersion of amorphous atorvastatin and one or more optional pharmaceutically acceptable excipients. The solid dispersion is prepared by mixing crystalline atorvastatin with a melt-processible polymer and an optional stabilizer and an optional plasticizer at a temperature sufficiently high to soften or melt the polymer and to melt or dissolve the crystalline atorvastatin in the polymer, thereby forming a dispersion of amorphous atorvastatin.06-16-2011
20110230539Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor - Compounds having a structure of Formula (A) are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are provided. Uses of compounds having a structure of Formula (F) for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.09-22-2011
20100029743ATORVASTATIN PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical formulations of atorvastatin or its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs or their mixtures; and processes for preparing the same, and their methods of use, treatment and administration. Further, the present invention relates to pharmaceutical compositions comprising an acid-solubility-enhanced form of atorvastatin or its salts.02-04-2010
20090209614GLUTAMINE-CONTAINING COMPOSITIONS AND A METHOD FOR INCREASING BLOOD FLOW USING SAME - The present invention provides a glutamine-containing composition which functions to increase blood flow. Glutamine is present in the composition in an amount of 25 mg/kg body weight to 150 mg/kg body weight. By administering the composition to a subject in need thereof, the blood flow in the capillary vessels can be efficiently increased, while inhibiting any side effects such as low blood pressure. The present invention also provides food or feed containing the composition for increasing blood flow.08-20-2009
20090209613Use of allymercaptocaptopril for treating or preventing obesity and obesity related diseases - Use of allylmercaptocaptopril for treating or preventing obesity and/or an obesity related disease or disorder is disclosed.08-20-2009
20090105328Amino Acid Compounds - An Amino Acid Compound is described. The Amino Acid Compound may comprise an Amino Acid and one of a Nitrate and a Nitrite. The Amino Acid may be one of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine.04-23-2009
20090209612PROCESS FOR THE PREPARATION OF ATORVASTATIN - The invention relates to processes for the preparation of atorvastatin. Atorvastatin is known by the chemical name [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid. The hemi-calcium salt of atorvastatin is useful as an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase). The invention also relates to pharmaceutical compositions that include the atorvastatin or a pharmaceutically acceptable salt thereof and to use of said compositions for treating hypolipidemia, hypocholesterolemia and atherosclerosis.08-20-2009
20090247603Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor - The present invention is a new stable drug composition particularly suitable for use as an antihypercholesterolaemic or antihyperlipidaemic agent. The present invention is specifically a drug composition comprising a pharmaceutical, a complexing agent and a surfactant, and a method for manufacturing same. When applied to unstable drugs with low solubility and poor bioavailability, like HMG-CoA reductase inhibitors and especially atorvastatin calcium amorphous form, the resulting drug composition is more stable and is characterized by an improved dissolution profile.10-01-2009
20080275103Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic - The invention relates to a compound represented by general formula (I) wherein Z represents N, O or S, and A represents a CH group, a nitrogen atom or an NL11-06-2008
20090221667Process for Annealing Amorphous Atorvastatin - Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.09-03-2009
20090239927Statin and Omega-3 Fatty Acids For Lipid Therapy - A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.09-24-2009
20100152275Drug or Supplement Combination with Conjugated Linoleic Acid for Fat Loss in Mammals - Food, feed or drug combinations with conjugated linoleic acid are described that cause enhanced fat loss in mammals more efficiently than any of the individual components of the combination. Food, feed, or drugs that activate AMP activated protein kinase, agonists of nuclear receptors that bind RXR in adipocytes, or statin inhibitors were found to be more effective for fat loss when combined with conjugated linoleic acid.06-17-2010
20090082420DEUTERIUM-ENRICHED VILDAGLIPTIN - The present application describes deuterium-enriched vildagliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-26-2009
20100234442Compositions and Methods for Treatment and Prevention of Cardiovascular Disease - The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and cardiology. In one aspect, the invention provides compositions comprising enalapril and simvastatin for use in methods for the treatment and/or prevention of cardiovascular disease, and to the use of such compositions in the manufacture of products for such treatment and/or prevention. In another aspect, the invention provides methods for the treatment and/or prevention of cardiovascular disease using compositions comprising enalapril, simvastatin and acetylsalicylic acid. The compositions and methods of the invention are useful in the treatment and prevention of cardiovascular disease in a variety of animals, particularly humans.09-16-2010
20090076126DEUTERIUM-ENRICHED ENALAPRIL - The present application describes deuterium-enriched alendronate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20130190377Novel Lactams - The present invention relates to novel lactams of formulae (I) and (II). The present invention further relates to the use of these compounds in the treatment of microbial infections and microbial contamination of surfaces, particularly infections and surface contaminations characterised by biofilm formation. Further provided are compounds of formula (I) and (II) substituted with acrylate or methacrylate groups and their attachment to surfaces or polymers to inhibit microbial contamination.07-25-2013
20100222405MAGNESIUM SALTS OF HMG-COA REDUCTASE INHIBITORS - The present invention relates to magnesium salts of HMG-CoA reductase inhibitors, processes for their preparation, pharmaceutical compositions thereof and methods of using compositions to treat mammals suffering from hypercholesterolemia.09-02-2010
20090318530PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS - The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker compound of formula (I)12-24-2009
20110130438ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS - Provided herein are compounds of the formula (I):06-02-2011
20130131138NOVEL FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b,d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4- -[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID MAGNESIUM - Novel forms of atorvastatin magnesium salt designated Form A, Form B, Form C, Form D, Form E, and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods utilizing the compounds for treatment of hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease are described.05-23-2013
20130137745STABILIZED STATIN FORMULATIONS - The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same.05-30-2013
20090069403COMPOSITION AND METHOD FOR REDUCING ALLERGEN - This invention relates to an allergen-reducing composition comprising a hydroxyproline derivative, a polymer thereof, or a salt of such a derivative or polymer, which is capable of reducing the allergenicity of mites, pollens, or other allergens and is capable of imparting functions of reducing allergenicity to fibers or textiles such as a carpet, a tatami mat, a bed cloth, a curtain, clothing, a stuffed animal, a mask, a filter material, or a dust bag for an electric vacuum cleaner without discoloration; and a method for reducing allergens using such composition.03-12-2009
20100324111COMBINATION COMPRISING PYRROLIDONE-5-CARBOXYLIC ACID AND AT LEAST ONE COMPOUND FROM CITRULLINE, ARGININE AND ASPRAGINE, AND USE THEREOF IN THE TRATMENT OF ATOPIC DERMATITIS - The present invention relates to a composition comprising, in a physiologically acceptable carrier, pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, in racemic or isomer form, and salts thereof, for the preparation of a medicament for use in the treatment and/or prevention of atopic dermatitis.12-23-2010
20110245317USE OF ORGANIC COMPOUNDS - This application is directed to methods for improving glucose control by administering metformin in combination with a DPP-IV inhibitor to a patient in need thereof, in an amount sufficient to control the glucose level over an extended period of time.10-06-2011
20110178151COMPOUNDS AND METHODS OF TREATING OBESITY - The present invention relates to novel fatty acid derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as agents for the treatment of obesity and related disorders, and for improving cognition.07-21-2011
20100144827NOVEL CONJUGATES OF POLYUNSATURATED FATTY ACIDS WITH AMINES AND THERAPEUTIC USES THEREOF - The present application discloses conjugates comprising an aminic moiety covalently linked to a hydrophobic moiety, through an amidic bond, which are selective inhibitors of COX-2 enzyme and can be beneficially used in the treatment of various inflammatory disease or disorder and cancer.06-10-2010
20110124705PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - Prodrugs of alpha-2-delta ligands, pharmaceutical compositions of prodrugs of alpha-2-delta ligands, methods of making prodrugs of alpha-2-delta ligands, and methods of using prodrugs of alpha-2-delta ligands and pharmaceutical compositions of prodrugs of alpha-2-delta ligands to treat various diseases are disclosed.05-26-2011
20110124704DEUTERIUM-ENRICHED ATORVASTATIN - The present application describes deuterium-enriched atorvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.05-26-2011
20090042969Use of Specific Trifluoromethyl Ketones for Preventing and Treating Pancreatitis - The present invention relates to the use of specific trifluoromethyl ketones for preventing and treating pancreatitis and, more particularly, chronic pancreatitis or chronically recurring pancreatitis.02-12-2009
20090215854ANTIMICROBIAL COMPOSITIONS, PRODUCTS AND METHODS EMPLOYING SAME - Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respiratory syricytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large head group; a branched alkyl chain and an unsaturated alkyl chain. Further, products incorporating the antimicrobial compositions of the present invention and methods of using the antimicrobial compositions and products disclosed herein.08-27-2009
20090215856Methods for monitoring IL-18 - This invention relates to methods for monitoring IL-18.08-27-2009
20090215855New Crystalline Atorvastatin Hemicalcium Salt Polymorph Form - The present invention relates to a new crystalline polymorph B-52 form of atorvastatin hemicalcium salt [A[(3R,5R)-7-[3-phenyl-4-[(phenyl carbamoyl]-2-(4-fluorophenyl)-5-(1-methylethyl)-1H-pyrrole-1-yl]-3,5-dihydroxy-heptanoic acid calcium salt (2:1)], medicinal preparations containing the new polymorph form, process for the preparation thereof and the use of the new polymorph form for the preparation of medicinal products.08-27-2009
20110152342STABILIZED PHARMACEUTICAL COMPOSITION - A pharmaceutical composition is provided which can easily be prepared and which can prevent decomposition of an aminoacetylpyrrolidine carbonitrile derivative, as an effective component, which derivative is in general instable in a pharmaceutical composition.06-23-2011
20110152341CLEAVAGE OF B-AMYLOID PRECURSOR PROTEIN - Methods and means for the identification of meprin-α and meprin-β as novel β-secretases and antagonists thereof for use in the treatment of amyloidosis.06-23-2011
20110098335NOVEL COMPOUNDS - The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof,04-28-2011
20110098334NOVEL CRYSTALLINE FORM OF CALCIUM ZOFENOPRIL - The present invention relates to a novel anhydrous crystalline form of zofenopril calcium of formula (I), chemically known as (4S)-1-[(2S)-3-(benzoylthio)-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt or hemi-calcium salt. The present invention further relates to a process for the preparation of the new crystalline form of zofenopril calcium, its use in pharmaceutical compositions and the use of the new crystalline form and compositions in the treatment of hypertension and various other diseases.04-28-2011
20110257240STABILIZED STATIN FORMULATIONS - The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same.10-20-2011
20100120889SKIN CARE COMPOSITION FOR ACCELERATED PRODUCTION OF COLLAGEN PROTEINS AND METHOD OF FABRICATING THE SAME - A liquid solution for topical application to the skin of an animal consists of solutes and a solvent, where the solutes include ascorbate, tropocollagen factors, copper, and zinc gluconate. The tropocollagen factors include L-proline, glycine and L-lysine.05-13-2010
20110160273CO-CRYSTALS OF DULOXETINE AND COX-INHIBITORS FOR THE TREATMENT OF PAIN - The present invention relates to co-crystals of duloxetine and co-crystal formers selected from COX-INHIBITORs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.06-30-2011
20100004311EXCITATORY AMINO ACID INHIBITORS FOR TREATING SENSITIVE SKINS - Sensitive human skin/scalp/mucous membrane conditions, for example skin irritation and/or dry patches and/or erythemas and/or dysaesthesic sensations and/or sensations of heating and/or pruritus, are therapeutically treated by topically applying thereto an effective condition-alleviating amount of at least one inhibitor of at least one excitatory amino acid.01-07-2010
20090118352Broad spectrum microbicidal and spermicidal compositions and methods - The present invention relates to microbicidal and spermicidal compositions, methods and topical pharmaceutical compositions containing N-cocoyl amino acid pyrrolidone carboxylates (N-cocoyl amino acid pyrrolidone salts, CAPS) as active ingredients. The invention is for the prevention and control of sexually transmitted diseases and for the prevention of pregnancy. The microbicidal spectrum of the invention includes various STD pathogens, HIV viruses as well as gram positive and negative bacteria, and yeasts. Spermicidal barriers containing the compositions are also provided.05-07-2009
20080287521Crystalline Forms Of [R-(R*,R*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methyl- Ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium Salt (2:1) - Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.11-20-2008
20080214649Compositions and Therapeutic Use of N-Acetyl Aldosamines and N-Acetylamino Acids - Embodiments relate to compositions and use of compositions comprising amino acids and/or N-acetylamino acids for systemic administration to a mammal. Systemic administration is believed to alleviate or improve symptoms or syndromes associated with nervous, vascular, musculoskeletal, or cutaneous systems.09-04-2008
20100286227Compounds from Mycelium of Antrodia Cinnamomea and Use Thereof - The present invention relates to compounds from mycelium of 11-11-2010
20090176860ZOFENOPRIL CALCIUM - The present invention relates to zofenopril calcium form A substantially free of other forms of zofenopril calcium and to zofenopril calcium having a chemical purity of more than 98.5%. The present invention also relates to methods of preparing such zofenopril calcium. It further relates to compositions comprising such zofenopril calcium. Zofenopril calcium, (4S)-1-[(2S)-3-benzoylthio-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt, has the following structure:07-09-2009
20090176859Cathepsin cysteine protease inhibitors - The present invention relates to a novel class of compounds mainly, leucinamide-amino-carboxylate derivatives of formula (I) wherein Y is CR07-09-2009
20100144829Novel Receptor Antagonists and Their Methods of Use - The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor06-10-2010
20090306173CRYSTALLINE FORMS OF ATORVASTATIN MAGNESIUM - The present invention relates to crystalline forms of Atorvastatin magnesium and processes for their preparation. The crystalline forms of the present invention are designated as form X, form Y, form Z and form P of atorvastatin magnesium. The present invention further relates to pharmaceutical compositions comprising form X, form Y, form Z and form P of atorvastatin magnesium and method of using the crystalline forms.12-10-2009
20090082421Crystalline Form B4 of Atorvastatin Magnesium and a Process Thereof - Crystalline polymorphic form B4 of Atorvastatin magnesium of FIG. 03-26-2009
20100152274CRYSTALLINE FORMS OF ATORVASTATIN 4-(NITROOXY) BUTYL ESTER - The present invention relates to two crystalline forms designated as form A and form B, of (βR,δR)-2(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbon-yl]-1H-pyrrole-1-heptanoic acid 4-(nitrooxy)butyl ester (atorvastatin 4-(nitrooxy)butyl ester), represented by the formula (I), The invention also relates to processes for the preparation of the forms A and B, to pharmaceutical compositions comprising the two forms, and to their use for treating and/or preventing acute coronary syndromes, stroke, neurodegenerative disorders, such as Alzheimer's and Parkinson's disease as well as autoimmune diseases, such as multiple sclerosis.06-17-2010
20090143459Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms - The present invention provides novel forms of atorvastatin designated Forms VI, VII, VIII, IX, IXa, X, XI, XII, XIV, XVI and XVII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.06-04-2009
20090143458USE OF ACE INHIBITORS AND/OR ANGIOSTENSIN II RECEPTOR ANTAGONISTS FOR THE IMPROVING AND/OR MAINTAINING THE SKIN TONE AND FOR THE TREATMENT OF SKIN AGEING - The present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist of the preparation of a medicament for the treatment of skin ageing or wrinkling. Furthermore, the present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a cosmetic composition.06-04-2009
20090281162Crystalline forms of atorvastatin - The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B1, B2, C, D and E. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.11-12-2009
20100099734AMINO ACID AND ITS USES - This invention relates to a supplement, the use thereof and method for supplementing the concentration of free cellular L-proline in an organism, for restricting dehydration of such an organism, the supplement comprising an effective amount of free L-proline. The supplement is effective in reducing the levels of free radicals in organisms experiencing water stress. This invention further relates to a method of treating dehydration in humans and animals including the step of administering to an individual in need thereof an effective amount of a supplement according to the third aspect of the invention. An effective amount of free L-proline is typically between 20 and 1000 mg, preferably 100 mg free L-proline per kilogram body mass of the organism, three times a day.04-22-2010
20080280971DEUTERIUM-ENRICHED ATORVASTATIN - The present application describes deuterium-enriched atorvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.11-13-2008
20120046335SOLID STATES OF ATORVASTATIN POTASSIUM - Atorvastatin potassium crystalline Forms A, B, E, F, and G are provided. Also provided are methods of preparing atorvastatin potassium crystalline Forms A, B, E, F, and G. Atorvastatin potassium crystalline Forms A, B, E, F, and G may be used to prepare pharmaceutical compositions useful for the treatment of hypercholesterolemia or hyperlipidemia.02-23-2012
20120010264NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT - The present invention provides a medicament for preventing and/or treating cognitive impairment, in particular Alzheimer's dementia, comprising 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propionic acid or a pharmaceutically acceptable salt or solvate thereof.01-12-2012
20120059040NOVEL FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-P- HENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID MAGNESIUM - Novel forms of atorvastatin magnesium salt designated Form A, Form B, Form C, Form D, Form E, and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods utilizing the compounds for treatment of hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease are described.03-08-2012
20090137658BENZENESULFONIC ACID SALT COMPOUNDS - Besylate salts of trans-4-({2-[(2S)-2-cyano-pyrrolidinyl]-2-oxoethyl}amino)-N,N-dimethylcyclohexanecarboxamide are described as well as methods of using the same in the treatment of disorders characterized by hyperglycemia.05-28-2009
20110092563STATIN AND OMEGA-3 FATTY ACIDS FOR LIPID THERAPY - A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.04-21-2011
20120071538PHARMACEUTICAL FORMULATONS - Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.03-22-2012
20120309811P-GLYCOPROTEIN-SPECIFIC NON-COMPETITIVE PEPTIDE AND PEPTIDOMIMETIC MODULATORS - The invention relates to a compound having structure (I), which acts as a non-competitive specific inhibitor of P-glycoprotein (P-gp for “Pleiotropic glycoprotein”) and which can be used as a drug, particularly for improving the effectiveness of chemotherapy treatments. The invention is therefore suitable for use in the medical field, particularly for the chemotherapeutic treatment of cancers or infections.12-06-2012
20110065769Transdermal delivery of ionizable drugs - Provided is a composition for transdermal administration. The composition comprises a therapeutic agent having a net charge at skin pH and a topical penetration enhancer having a net charge at skin pH opposite the net charge of the therapeutic agent. In another aspect, a method is provided for increasing the transdermal absorption of a therapeutic agent. The method comprises forming a therapeutic composition at skin pH by combining a therapeutic agent having a net charge at skin pH with a topical penetration enhancer having a net charge at skin pH opposite the net charge of the therapeutic agent, the ratio of topical penetration enhancer to therapeutic agent being sufficient to increase absorption of therapeutic agent compared to absorption of therapeutic agent in the absence of topical penetration enhancer, and administering the therapeutic composition to a patient in need thereof.03-17-2011
20080269315Crystalline form - The present invention is directed to the novel polymorphic Form F of Atorvastatin calcium, processes for the preparation thereof and pharmaceutical compositions comprising this crystalline form.10-30-2008
20100093827METHOD FOR TOPICAL TREATMENT OF TAR-RESPONSIVE DERMATOLOGICAL DISORDERS - A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder, the composition including a wax and a therapeutically effective amount of tar for topical treatment of the tar-responsive dermatological disorder, the composition being in liquid form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal.04-15-2010
20120316217 COMBINATION FOR THE TREATMENT OF OSTEOARTHRITIS - The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic viscosity-controlling polymer, and/or lysine and/or leucine, to prepare a composition for the treatment of osteoarthritis.12-13-2012
20110118328NOVEL CRYSTALLINE FORMS - The present invention relates to two novel crystalline forms of zofenopril calcium, to processes for their preparation and their use in pharmaceutical compositions.05-19-2011
20120165386STABLE ORAL PHARMACEUTIAL COMPOSITION OF ATORVASTATIN - The present invention relates to a stable oral pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof and an alkalizing agent, wherein the buffering capacity of the composition is between 2 to 5.06-28-2012
20120214858IMIDAMIDE SPHINGOSINE KINASE INHIBITORS - Imidamide (amidine) analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumors.08-23-2012
20100069459NOVEL FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-P- HENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID MAGNESIUM - Novel forms of atorvastatin magnesium salt designated Form A, Form B, Form C, Form D, Form E, and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods utilizing the compounds for treatment of hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease are described.03-18-2010
20100173970C-NITROSO-DERIVED NITROXYL DONORS - Active compounds of Formula I are described:07-08-2010
20120252865CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The present invention relates to new carbamate derivatives of formula I, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders, such as neuropathic pain and anxiety.10-04-2012
20120178789NOVEL PYRROLIDINES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE - The present invention relates to compounds of the general formula: (I) wherein ring B, R07-12-2012
201002922955-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS - The present invention provides a compound of Formula (IA) or a pharmaceutically acceptable salt thereof: 11-18-2010
20100292294Compositions Comprising a Physiological Coolant - The present invention concerns enhancements in the cooling effects of certain physiological coolant-containing compositions such as topically applied cosmetic, toiletry or pharmaceutical products, wherein the cooling effect of the physiological coolants is enhanced by the addition of a substance according to formula (I) or dermatologically acceptable salts thereof:11-18-2010
20120220643Amino Acid Compounds - A method for increasing the vasodilative characteristics of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, Phenylalanine, Carnitine, Taurine, and Betaine.08-30-2012
20120220642Amino Acid Compounds - Methods for increasing the bioabsorption of amino acids and for preventing the development of nitrate tolerances in a human or animal are disclosed. The methods include administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, Phenylalanine, Carnitine, Taurine, and Betaine.08-30-2012
20110112165ATORVASTATIN-ALISKIREN - A new compound in which atorvastatin and aliskiren are covalently bound, salts of this compound, pharmaceutical compositions thereof, as well the use of this compound as a medicament and as an impurity standard are provided. Furthermore, a 0 process for the preparation of a compound in which atorvastatin and aliskiren are covalently bound, a method for analyzing a sample of atorvastatin and/or aliskiren, and a method for determining the retention time on a chromatographic system for atorvastatin and/or aliskiren are provided.05-12-2011
20080300293COMBINATION OF AN DPP-IV INHIBITOR AND A PPAR-ALPHA COMPOUND - The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further PPARα compound, preferably selected from the group consisting of fenofibrate, micronized fenofibrate, bezafibrate, gemfibrazil and ciprofibrate for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by DPP-IV and PPARα, in particular diabetes, more especially type 2 diabetes mellitus, conditions of IGT, conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity, dyslipidemia and osteoporosis.12-04-2008
20110046199SMALL MOLECULE INHIBITORS OF HIV PROTEASES - Described herein are compounds, compositions, and methods for treating HIV and related diseases.02-24-2011
20110237642Process for Forming Amorphous Atorvastatin - A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solutilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.09-29-2011
20100234443Combinations of statins and anti-obesity agent - Co-therapy of an anti-obesity agent, a statin, is disclosed along with fixed combinations thereof. Atorvastatin and orlistat are preferred as the various components.09-16-2010
20120277280PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS - The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound.11-01-2012
20120329851D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of central nervous system disorders.12-27-2012
20120329852COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT - Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.12-27-2012
20110319467Absorption Enhancement of Statins and Omega Fatty Acids - A composition and method to enhance absorption and bioavailability of Statin and Omega fatty acids consumed by humans and in an anhydrous base is presented.12-29-2011
20110319466Method and composition for treating heart failure - A method and composition for treating, preventing or ameliorating heart failure, cardiac hypertrophy, and/or myocardial dysfunction includes administering a therapeutically effective amount of a HDAC inhibitor, such as phenylbutyrate, in combination with an ACE inhibitor, such as captopril.12-29-2011
20120289576Process for Forming Amorphous Atorvastatin - A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.11-15-2012
20100168201Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-P- yrrole-1-Heptanoic Acid Magnesium Salt (2:1) - Crystalline and amorphous polymorphic forms of Atorvastatin magnesium and processes for their preparation are claimed.07-01-2010
20100130583PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS - The invention relates to quaternary α-aminocarboxyamide derivatives of formula (I) and their pharmaceutically salts or solvates05-27-2010
20110160274FENOFIBRATE FORMULATION WITH ENHANCED ORAL BIOAVAILABILITY - The present invention provides a formulation of fenofibrate with enhanced oral bioavailability, simplicity of design and manufacture and absence of food effect. The formulation comprises fenofibrate dissolved in a lipophilic surfactant, with a hydrophilic surfactant optionally added. The formulation can be effectively used in the management and treatment of conditions such as hypertriglyceridemia, hypercholesterolemia and mixed dyslipidemia, and can also be effective at lower doses as compared to commercially available products. The invention additionally relates to the process of manufacture of the formulation and to dosage forms comprising the same.06-30-2011
20080249157Novel Inhibitors of the Lfa-1/Icam-1 Interaction and Uses Thereof - The invention relates to the treatment of disorders or diseases mediated by LFA-1/ICAM-1 molecular interaction. This is based on the use of novel chemical compounds capable of inhibiting said interaction, and more particularly, to pharmaceutical compositions containing these compounds.10-09-2008
20080249156Combinations of statins and anti-obesity agent and glitazones - Co-therapy of an anti-obesity agent, a statin, and a glitazone is disclosed along with fixed combinations thereof. Atorvastatin, rosiglitazone, and orlistat are preferred as the various components. Non-glitazone antidiabetic agents may be optionally added to the therapy and/or to the fixed combination product.10-09-2008
20080234360Attractants for Insects Such as Flies - A composition containing at least two members of the group consisting of propionic acid, benzoic acid, 2,6-dimethoxyphenol, 2-acetylpyrrole, 2-hydroxy-3-methyl-2-cyclopentanone, 2-methyltetrahydrofuran-3-one, and 3-methylbutanal; and water, and optionally a carrier or carrier material. The composition is useful for attracting insects (e.g., flies).09-25-2008
20080227847Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use - The present invention relates to novel amino acid salts of fumaric acid monoalkylesters. The salts are suitable for use as active substances in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders.09-18-2008
20110263673Atropisomers of (Hydroxyalkyl) Pyrrole Derivatives - The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases. The compound is an atropisomer of a compound represented by the following general formula (I): wherein R10-27-2011
20080221200Combination of Organic Compounds - The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and comprising at least one immunosuppressive or immunomodulator agent, or a pharmaceutically acceptable salt thereof.09-11-2008
20120252866Age Inhibitors - The invention relates to a compound having general formula I, wherein: X represents CH10-04-2012
20080214651Crystalline forms of [R-(R*, R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) - Novel crystalline forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.09-04-2008
20080214650Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel process for preparing other forms - The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.09-04-2008
20110218228CRYSTALLINE SODIUM ATORVASTATIN - Crystalline sodium atorvastatin, compositions containing the same and methods for the production thereof.09-08-2011
20080200534Cosmetic and Pharmaceutical Compositions Comprising Lauroyl Proline and an Ester of Anhydrohexitol and of an Aliphatic Carboxylic Acid - Composition (A) containing, for 100% of its mass: from 10 mass % to 90 mass % of N-lauroyl proline (I) and from 10 mass % to 90 mass % of an ester (II) of anhydrohexitol and of a saturated or unsaturated, linear or branched aliphatic carboxylic acid containing from 12 to 20 carbon atoms optionally substituted with one or more hydroxyl groups, or of a mixture of esters (II); use thereof for preparing a medicament with lipolytic activity, intended to induce slimming of the human or animal body and/or the reduction of cellulite or of the orange-feel appearance; cosmetic formulation or therapeutic composition containing same; process for the preparation thereof and process for the solubilization of N-lauroyl proline (I) in a liquid medium.08-21-2008
20080200533Drug or Pharmaceutical Compounds and a Preparation Thereof - The administration of pharmaceuticals of drugs which are having less solubility, lower bioavailability, lower bioabsorbability, less rate of absorption has become a big challenge in day to day life. Therefore an attempt has been made to prepare a complex modified form of the said pharmaceutical or drug such that the modified complex drugs or pharmaceuticals exhibits the enhanced properties of solubility, bioavailability, bioabsorbability and rate of absorption despite the increased complexity of the molecule. Surprisingly such modification was found to enhance retentivity of the active drug ingredient in the blood. Higher amounts of the active drug ingredient has shown lower toxicity.08-21-2008
20130197054Composition Based on Vegetable Extract and Methods for the Treatment of Cutaneous Inflammatory Forms, in Particular Psoriasis - The present invention concerns, in one aspect, a composition comprising an extract of beet plant in a biologically active amount and a physiologically acceptable excipient or carrier. The composition of the invention finds application in the dermatological or cosmetic treatment of inflammatory skin affection such as reddening or psoriatic lesions.08-01-2013
20130184322NOVEL DIPEPTIDYL-PEPTIDASE-IV INHIBITORS - The invention comprises novel inhibitors of dipeptidyl peptidase IV (DPP-IV) with beta blocker activity, pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP-IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP-IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, hypertension, and glaucoma of such other enumerated conditions as can be treated with inhibitors of DPP-IV and beta blockers.07-18-2013
20130102649SUBSTITUTED BIARYL ALKYL AMIDES - Disclosed herein are substituted biaryl alkyl amide compounds, methods of synthesizing substituted biaryl alkyl amide compounds and methods of treating diseases and/or conditions with substituted biaryl alkyl amide compounds.04-25-2013
20120302621D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS - The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders and the enhancement of the visual function.11-29-2012
20120095072Crystalline Sodium Atorvastatin - Crystalline sodium atorvastatin, compositions containing the same and methods for the production thereof.04-19-2012

Patent applications in class C=X bonded directly to the five-membered hetero ring by nonionic bonding (X is chalcogen)